Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

NCT ID: NCT02474550

Last Updated: 2017-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-04-30

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim. The investigators will prospectively collect clinical data and treatment outcome of patients with DLBCL who use prophylactic pegylated-filgrastim.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Newly diagnosed DLBCL patients treated with R-CHOP chemotherapy
* Prphylactic peg-filgrastim on the day after chemotherapy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diffuse Large B Cell Lymphoma Neutropenia, Febrile

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CISL 14-03

* Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL).
* Aged 19 or more
* Treated with R-CHOP therapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 19 or older
* newly diagnosed with DLBCL
* R-CHOP chemotherapy
* offer informed consent

Exclusion Criteria

* other subtype of NHL
* concomitant other cancer
* previous chemotherapy or radiotherapy
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ajou University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Seong Hyun Jeong

Associate

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Seong Hyun Jeong, M.D

Role: PRINCIPAL_INVESTIGATOR

Ajou University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ajou Universtiy School of Medicine

Suwon, Kyeonggi, South Korea

Site Status RECRUITING

Soon Chun Yang University Hospital Bucheon

Bucheon-si, , South Korea

Site Status RECRUITING

Busan Paik Hospital

Busan, , South Korea

Site Status RECRUITING

Chungbuk National University Hospital

Cheongju-si, , South Korea

Site Status RECRUITING

Keimyung Univerisity Dongsan Medical Center

Daegu, , South Korea

Site Status RECRUITING

Yeungnam University Hospital

Daegu, , South Korea

Site Status RECRUITING

Chungnam National University Hospital

Daejeon, , South Korea

Site Status RECRUITING

Inje University Ilsan Paik Hospital

Ilsan, , South Korea

Site Status RECRUITING

Gachon University Gill Hospital

Incheon, , South Korea

Site Status RECRUITING

Chonbuk Nationa University Hospital

Jeonju, , South Korea

Site Status RECRUITING

Gyeongsang National University Hospital

Jinju, , South Korea

Site Status RECRUITING

Asan Medical Center

Seoul, , South Korea

Site Status RECRUITING

Choong Ang University Hopspital

Seoul, , South Korea

Site Status RECRUITING

Hallym University Sacred Heart Hospital

Seoul, , South Korea

Site Status RECRUITING

Hanyang University Hospital

Seoul, , South Korea

Site Status RECRUITING

Hanyang University Medical Center

Seoul, , South Korea

Site Status RECRUITING

Inje University Sanggye Paik Hospital

Seoul, , South Korea

Site Status RECRUITING

Korea Cancer Center Hospital

Seoul, , South Korea

Site Status RECRUITING

Korea Institute of Radiological & Medical Science

Seoul, , South Korea

Site Status RECRUITING

Korea University Anam Hospital

Seoul, , South Korea

Site Status RECRUITING

Samsung Medical Center

Seoul, , South Korea

Site Status RECRUITING

Seoul National University Hospital

Seoul, , South Korea

Site Status RECRUITING

Ulsan University Hospital

Ulsan, , South Korea

Site Status RECRUITING

Wonju Severance Christian Hospital

Wŏnju, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Geum-Sook Jeong

Role: CONTACT

+82-31-219-5989

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Geum Sook Jeong, MS

Role: primary

+82-31-219-5990

Won Sik Lee

Role: primary

Hyejin Kang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AJIRB-MED-OBS-14-254

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.